Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/16/21 A | Issuer sale | Director | 45,000 | 0.0966% | ||
| 4/16/21 A | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 4/16/21 A | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -2.01% | -7.86% | +60.74% | +70.97% | 68.92B | |
| +3.84% | -11.02% | +8.59% | +57.43% | 51.9B | |
| +3.35% | +1.42% | +11.85% | +40.01% | 48.73B | |
| +0.51% | +1.51% | +27.96% | +31.43% | 43.13B | |
| +2.70% | -3.66% | +307.41% | +547.01% | 41.48B | |
| +0.69% | -3.44% | +9.52% | +96.59% | 39.96B | |
| +0.06% | -2.02% | +11.25% | +43.27% | 30.6B | |
| -0.84% | -9.06% | +36.89% | +0.41% | 26.01B | |
| -0.39% | -6.92% | -13.60% | -14.40% | 22.27B | |
| Average | +0.77% | -4.58% | +51.18% | +96.97% | 41.44B | |
| Weighted average by Cap. | +0.94% | -4.28% | +55.09% | +103.86% |
Employees
51
